SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

TransCode Therapeutics Says TTX-MC138 Met Phase 1a Safety Endpoint

TransCode Therapeutics reported that its TTX-MC138 met the primary safety endpoint in a Phase 1a trial.

RNAZ

Related stories